Metagenomi Therapeutics: Fourth Quarter Financial Results Overview

Metagenomi Therapeutics Reports Fourth Quarter Financial Results

Metagenomi Therapeutics, headquartered in Emeryville, California, announced a net loss of $22.5 million for the fourth quarter.

The company’s loss per share for the quarter was reported at 60 cents.

During the same period, Metagenomi generated $3.9 million in revenue.

For the full year, the genetic medicine firm recorded a total loss of $87.9 million, translating to $2.36 per share, with annual revenue reaching $25.2 million.

Financial data for this article was compiled with information from Zacks Investment Research and processed by Automated Insights.